Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
There was no statistically significant difference between amlodipine besylate and placebo in the primary endpoint of all-cause mortality (95% confidence limits from 8% reduction to 29% increase on amlodipine besylate)
It is contraindicated for patients with hypersensitivity, hypercalcemia, renal impairment, or sarcoidosis
FDA approval requires successful completion of multi-phase clinical trials for a specific indication
Their non-medical use carries health and legal risks
Dalziel, K
US$ 23.85
US$ 23.57
US$ 27.47
US$ 21.54
US$ 24.61
